July 16, 2009 11:01 PM
- Text
Lucky Number 12? Biogenerics Legislation Trudges Forward
(MoneyWatch) The biogenerics legislation that died in the last congress is slowly, painfully making its way through the current bunch of bureaucrats, as most folks expected it would when the Democrats took control.
The main issue raising everyone's hackles is exclusivity: how many years of protection should biotech drugs have before the generic makers get to piggy-back on their data and bring cheaper versions to market?
Here are the exclusivity options on the table: Congressman Henry Waxman (D-CA) and the Generic Pharmaceutical Association are angling for five years; the Obama Administration and the AARP recommend seven years; the Senate Health, Education, Labor and Pensions Committee voted for 12 years; Senator Ted Kennedy (D-MA) called for 13.5 years; and representatives Anna Eshoo (D-Calif.), Joe Barton (R-Texas) and Jay Inslee (D-Wash.) introduced a bill boasting 14 years.
As with everything else in politics, the debate is not without scandal. Slate reported that Senator Kennedy might have ulterior motives for his industry-friendly proposal, namely that Amgen Inc. has pledged $5 million to "help create the Edward M. Kennedy Institute for the United States Senate, a pricey 'Teddy Too' annex that Kennedy hopes to build alongside the John F. Kennedy Presidential Library and Museum."
Ironically, the Biotechnology Industry Organization, which is pushing for 12 to 14 years of exclusivity, took issue with Kennedy's proposal. According to a BioWorld Today article, BIO complained that Kennedy's measure actually provided just nine years of protection, and that some drugs could end up with zero if they are too similar to a previously approved product or get approved before the bill goes into effect.
For now, the Senate has settled on 12 years ?€" good news for industry, but hardly the end of the debate because it will have to be joined with whatever bill emerges from the House, where Waxman is lying in wait.
Roulette photo by WikiMedia Commons user Uutela, GNU Free
The main issue raising everyone's hackles is exclusivity: how many years of protection should biotech drugs have before the generic makers get to piggy-back on their data and bring cheaper versions to market?Here are the exclusivity options on the table: Congressman Henry Waxman (D-CA) and the Generic Pharmaceutical Association are angling for five years; the Obama Administration and the AARP recommend seven years; the Senate Health, Education, Labor and Pensions Committee voted for 12 years; Senator Ted Kennedy (D-MA) called for 13.5 years; and representatives Anna Eshoo (D-Calif.), Joe Barton (R-Texas) and Jay Inslee (D-Wash.) introduced a bill boasting 14 years.
As with everything else in politics, the debate is not without scandal. Slate reported that Senator Kennedy might have ulterior motives for his industry-friendly proposal, namely that Amgen Inc. has pledged $5 million to "help create the Edward M. Kennedy Institute for the United States Senate, a pricey 'Teddy Too' annex that Kennedy hopes to build alongside the John F. Kennedy Presidential Library and Museum."
Ironically, the Biotechnology Industry Organization, which is pushing for 12 to 14 years of exclusivity, took issue with Kennedy's proposal. According to a BioWorld Today article, BIO complained that Kennedy's measure actually provided just nine years of protection, and that some drugs could end up with zero if they are too similar to a previously approved product or get approved before the bill goes into effect.
For now, the Senate has settled on 12 years ?€" good news for industry, but hardly the end of the debate because it will have to be joined with whatever bill emerges from the House, where Waxman is lying in wait.
Roulette photo by WikiMedia Commons user Uutela, GNU Free
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Magic hit 17 3-pointers in 102-89 win over Heat
- Lin, Chandler lead Knicks over Wizards 107-93
- Delfino scores 25 as Bucks beat Raptors
- Parker scores 37, leads Spurs over 76ers 100-90
on Facebook Most Discussed Stories
on CBS News






